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Marked Impairment of Protease-Activated
Receptor Type 1-Mediated Vasodilation
and Fibrinolysis in Cigarette Smokers
Smoking, Thrombin, and Vascular Responses In Vivo
Ninian N. Lang, MRCP,* Ingibjörg J. Gu mundsdo´ttir, MRCP,* Nicholas A. Boon, MD, FRCP,†
Christopher A. Ludlam, PHD, FRCP,* Keith A. Fox, FRCP, FESC,* David E. Newby, PHD, FRCP*
Edinburgh, United Kingdom
Objectives We sought to test the hypothesis that cigarette smoking adversely alters protease-activated receptor type 1
(PAR-1)-mediated vascular effects in vivo in humans.
Background Distinct from its role in the coagulation cascade, thrombin exerts its major cellular and cardiovascular actions
via PAR-1. The activation of PAR-1 causes endothelium-dependent arterial vasodilation and the release of en-
dogenous fibrinolytic factors.
Methods Forearm blood flow was measured with venous occlusion plethysmography in 12 cigarette smokers and 12 age-
and gender-matched nonsmokers during intrabrachial infusions of PAR-1–activating-peptide (SFLLRN; 5 to 50
nmol/min), bradykinin (100 to 1,000 pmol/min), and sodium nitroprusside (2 to 8 g/min). Plasma tissue plas-
minogen activator (t-PA) and plasminogen-activator inhibitor 1 antigen and activity concentrations were mea-
sured throughout the experiment.
Results All agonists caused dose-dependent increases in forearm blood flow (p  0.0001 for all). Although bradykinin
and sodium nitroprusside caused similar vasodilation, SFLLRN-induced vasodilation was attenuated in smokers
(p  0.04). Smokers had modest reductions in bradykinin-induced active t-PA release (reduced by 37%, p 
0.03) and had a marked impairment of SFLLRN-induced t-PA antigen (p  0.02) and activity (p  0.006) re-
lease, with a 96% reduction in overall net t-PA antigen release. The use of SFLLRN also caused similar (p  NS)
increases in inactive plasminogen-activator inhibitor 1 in both smokers and nonsmokers (p  0.002 for both).
Conclusions Cigarette smoking causes marked impairment of PAR-1–mediated endothelial vasomotor and fibrinolytic func-
tion. Relative arterial stasis and near abolition of t-PA release will strongly promote clot propagation and vessel
occlusion. These findings suggest a major contribution of impaired endothelial PAR-1 action to the increased
atherothrombotic risk of cigarette smokers. (J Am Coll Cardiol 2008;52:33–9) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.003t
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mmoking tobacco remains one of the most important and
onsistent modifiable risk factors for myocardial infarc-
ion and fatal coronary artery disease (1). The recent
NTERHEART (A Study of Risk Factors for First
yocardial Infarction in 52 Countries and Over 27,000
ubjects) study revealed that smoking tobacco increases
rom the *Centre for Cardiovascular Science, University of Edinburgh; and †De-
artment of Cardiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
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edical Association Lansdell and Lawson Research Grant, United Kingdom. Drs.
ang and Gu mundsdo´ttir contributed equally to this work.t
Manuscript received January 7, 2008; revised manuscript received March 25, 2008,
ccepted April 2, 2008.he risk of nonfatal myocardial infarction by as much as
-fold (2). The pathophysiological mechanisms underly-
ng this association are likely to be a combination of
ccelerated atherosclerosis (3) and a propensity to acute
oronary thrombosis (1,4).
The endogenous fibrinolytic system is responsible for the
issolution of arterial thrombi that are frequently found on
he surface of atherosclerotic plaques at areas of endothelial
enudation (5,6). It is regulated by the profibrinolytic
actor, tissue plasminogen activator (t-PA), and its endog-
nous inhibitor, plasminogen-activator inhibitor type 1
PAI-1) (7–9). The rapid mobilization of t-PA from the
ndothelium is crucial, with thrombus dissolution being
uch more effective if t-PA is incorporated during, ratherhan after, thrombus formation (10). Indeed, acute stimu-
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PAI-1 Vasodilation and Fibrinolysis in Smokers July 1, 2008:33–9lated t-PA release predicts the
future risk of cardiovascular
events (11).
Thrombin plays a central role
in the coagulation cascade and
thrombosis. It is one of the most
powerful physiological agonists
in the cardiovascular system, and
its actions are fundamental to the
processes of atherothrombosis.
Distinct from its enzymatic role
in the coagulation cascade,
thrombin causes direct cellular
activation through stimulation of
a novel family of G-protein-
coupled receptors, protease-
activated receptors (PARs) (12).
hese receptors have a unique mechanism of activation
hereby agonist-induced proteolytic cleavage of the extra-
ellular domain reveals a short peptide sequence that re-
ains tethered and causes autoactivation of the receptor. To
ate, 4 different types of PARs have been identified:
AR-1, -3, and -4 are all activated by thrombin whereas
AR-2 is mainly activated by trypsin (13).
PAR-1 is the principal receptor that mediates the cardio-
ascular actions of thrombin. The hexapeptide, SFLLRN,
epresents the short peptide sequence revealed during
AR-1 activation and can be used as a selective agonist of
he human PAR-1 thrombin receptor without activation of
he coagulation cascade. Using SFLLRN, we have recently
escribed the in vivo effects of PAR-1 activation in platelets,
ndothelium, and vascular smooth muscle in humans. For
he first time, we were able to show that thrombin has
nique and contrasting effects in the human vasculature,
ncluding arterial dilation, venous constriction, platelet ac-
ivation, and tissue-type plasminogen activator (t-PA) re-
ease (14).
We, and others, have previously reported that pharma-
ological stimulation of acute t-PA release in the peripheral
15,16) and coronary (17,18) arterial circulations is mark-
dly attenuated in smokers. In this study, we hypothesized
hat smokers have impaired PAR-1–mediated vascular re-
ponses. We, therefore, examined PAR-1–mediated t-PA
elease and vasomotor responses in the forearm circulation
f cigarette smokers and healthy nonsmoking control
ubjects.
ethods
ubjects. Twelve healthy cigarette smokers (5 to 20 ciga-
ettes/day) and 12 age- and gender-matched nonsmokers
etween ages 20 and 46 years participated in the study,
hich was undertaken with the approval of the local
esearch ethics committee and in accordance with the
eclaration of Helsinki. The written informed consent of
Abbreviations
and Acronyms
ANOVA  analysis of
variance
EDHF  endothelium
derived hyperpolarizing
factor
NO  nitric oxide
PAI-1  plasminogen
activator inhibitor type 1
PAR  protease-activated
receptor
t-PA  tissue-type
plasminogen activator
vWF  von Willebrand
factorach subject was obtained before entry into the study. (xclusion criteria included a history of asthma, hyperten-
ion, diabetes mellitus, coagulopathy, hyperlipidemia, or
ascular disease. Control subjects were lifelong nonsmokers
nd were not exposed to regular environmental tobacco
moke. Smokers had a history of regular daily cigarette
moking of at least 5 years and maintained their normal
moking habits in the week before attendance.
None of the subjects received vasoactive or nonsteroidal
nti-inflammatory drugs in the week before the study, and
ll abstained from alcohol for 24 h before and from food,
obacco, and caffeine-containing drinks on the day of the
tudy. All studies were performed in a quiet, temperature-
ontrolled room maintained at 22°C to 24°C.
ntra-arterial drug administration. All subjects under-
ent brachial artery cannulation with a 27 standard-wire-
auge steel needle. The intra-arterial infusion rate was kept
onstant at 1 ml/min throughout all studies. Forearm blood
ow was measured in the infused and noninfused arms by
enous occlusion plethysmography with mercury-in-silastic
train gauges as described previously (15,19). Supine heart
ate and blood pressure were monitored at intervals
hroughout each study with the use of a semiautomated
oninvasive oscillometric sphygmomanometer.
After a 20-min intra-arterial infusion of 0.9% saline, the
lycoprotein IIb/IIIa antagonist, tirofiban (1.25 g/min;
erck, Sharp and Dohme, Hoddesdon, United Kingdom),
as infused and continued throughout the study to inhibit
otential PAR-1-induced platelet aggregation. This dose of
irofiban does not affect forearm blood flow (14).
During tirofiban administration, subjects received intra-
rterial infusions of the PAR-1–activating peptide,
FLLRN (5, 15, and 50 nmol/min; Clinalfa, Läufelfingen,
witzerland), bradykinin (an endothelium-dependent vaso-
ilator that causes the release of t-PA; 100, 300, and 1,000
mol/min; Clinalfa), and sodium nitroprusside (an
ndothelium-independent vasodilator that does not release
-PA; 2, 4, and 8 g/min; David Bull Laboratories, War-
ick, United Kingdom). Study drugs were infused in
andom order for 10 min at each dose and were separated by
20-min infusion of 0.9% saline.
lood sampling. Venous cannulae (17-gauge) were in-
erted into large subcutaneous veins of the antecubital fossae
f both arms. Blood samples were drawn simultaneously
rom each arm at the beginning of the study and during
nfusion of each dose of PAR-1–activating peptide
SFLLRN), bradykinin, and sodium nitroprusside. Venous
lood was collected into acidified buffered citrate (Stabilyte,
rinity Biotech Plc, Co., Wicklow, Ireland; for t-PA assays)
nd into citrate (BD Vacutainer, BD UK Ltd., Oxford,
nited Kingdom; for PAI-1 and von Willebrand factor
vWF] assays). Samples were kept on ice before centrifuga-
ion at 2,000 g for 30 min at 4°C. Platelet-free plasma was
ecanted and stored at 80°C before assay. Plasma t-PA
ntigen and activity (t-PA Combi Actibind Elisa Kit,
echnoclone, Vienna, Austria), PAI-1 antigen and activityElitest PAI-1 antigen and Zymutest PAI-1 Activity, Hy-
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July 1, 2008:33–9 PAI-1 Vasodilation and Fibrinolysis in Smokershen Biomed, Neuville-Sur-Oise, France), and vWF anti-
en (Dako A/S, Glostrup, Denmark) concentrations were
etermined with the use of enzyme-linked immunosorbent
ssays. Full blood count and hematocrit were measured at
aseline and the end of the study.
ata analysis and statistics. Forearm plethysmographic
ata were analyzed as described previously (19). Estimated
et release of plasma t-PA, PAI-1, and vWF has been
efined previously as the product of the infused forearm
lasma flow (based on the mean hematocrit and the infused
orearm blood flow) and the concentration difference be-
ween the infused and noninfused arms (19). Variables are
eported as mean  SEM and analyzed with repeated
easures analysis of variance (ANOVA) and a 2-tailed
tudent t test as appropriate. Statistical analysis was per-
ormed with GraphPad Prism (GraphPad Software, San
iego, California) and statistical significance taken at the
% level. The authors had full access to the data and take
esponsibility for its integrity. All authors have read and
greed to the report as written.
esults
here were no differences in baseline characteristics be-
ween cigarette smokers and nonsmokers (Table 1). There
ere no changes in blood pressure, heart rate, or hematocrit
data not shown) during the study. Smokers had a mean
igarette consumption of 15  1 cigarettes per day over a
ean period of 9  2 years (7  2 pack-years).
orearm blood flow. The use of tirofiban did not affect
orearm blood flow (data not shown). Intra-arterial sodium
itroprusside, bradykinin, and the PAR-1–activating pep-
ide, SFLLRN, all caused dose-dependent vasodilation in
he infused arm of smokers and nonsmokers (p 0.0001 for
ll; ANOVA). There were no changes in blood flow in the
oninfused arm (data not shown).
Although there was no difference with bradykinin (p 
.64; ANOVA smokers vs. nonsmokers), vasodilatation to
FLLRN was attenuated in smokers (p  0.044; ANOVA
mokers vs. nonsmokers). Endothelium-independent vaso-
ilation evoked by the use of sodium nitroprusside was
imilar in both groups (p  0.74; ANOVA smokers vs.
onsmokers) (Fig. 1).
lasma fibrinolytic and hemostatic factors. Baseline
lasma t-PA antigen and activity (Table 2) and vWF
ntigen (Table 3) concentrations were similar in smokers
nd nonsmokers. There appeared to be a trend toward
aseline Subject Characteristics
Table 1 Baseline Subject Characteristics
Nonsmokers Smokers
Age, yrs 26 2 29 2
Gender, male/female 12/0 12/0
Body mass index, kg/m2 24 1 27 1
Mean arterial pressure, mm Hg 97 2 99 2
Heart rate, beats/min 66 2 64 2Sreater absolute plasma PAI-1 antigen and activity concen-
rations in smokers, but this difference did not reach
tatistical significance (smokers vs. nonsmokers: PAI-1
ntigen, p  0.07 and p  0.10, and PAI-1 activity, p 
.18 and p  0.24; infused and noninfused arms, respec-
ively) (Table 4).
The use of SFLLRN caused a dose-dependent net release
f t-PA antigen in nonsmokers (p  0.0005; ANOVA) but
ot smokers (p  0.18; ANOVA) (Fig. 2). In comparison
ith nonsmokers, the release of t-PA antigen and activity by
Figure 1 Forearm Arterial Vasodilation
in Smokers and NonSmokers
Forearm arterial vasodilatation induced by SFLLRN (squares, top panel), brady-
kinin (circles, middle panel), and sodium nitroprusside (triangles, bottom
panel) in smokers (blue symbols) and nonsmokers (red symbols). *p  0.05.
NS  nonsignificant (analysis of variance, smokers vs. nonsmokers).Baseline hematocrit 0.42 0.01 0.42 0.01 FLLRN was markedly attenuated in smokers (p  0.02
a
S
a
a
s
a
a
N
a
0
d
f
s
i
(
B
a
0
e
a
s
D
T
t
p
o
f
fi
fi
l
a
S
r
s
n
n
o
i
B
s
i
a
A
O 001, §p
36 Lang et al. JACC Vol. 52, No. 1, 2008
PAI-1 Vasodilation and Fibrinolysis in Smokers July 1, 2008:33–9nd p  0.006, respectively; ANOVA). However,
FLLRN induced a dose-dependent net release of PAI-1
ntigen release in both nonsmokers (p  0.0002; ANOVA)
nd smokers (p  0.001; ANOVA). The response was
imilar in both groups (p  0.36; ANOVA) and was
ssociated with no change in net PAI-1 activity (pNS for
ll; ANOVA [data not shown]) or vWF antigen release (p 
S; ANOVA) (Table 3).
Bradykinin caused a dose-dependent net release of t-PA
ntigen and activity in both smokers and nonsmokers (p 
.01 for all; ANOVA). Bradykinin also evoked a dose-
ependent increase in absolute t-PA activity in the nonin-
used arm of both nonsmokers (p  0.0001; ANOVA) and
mokers (p 0.008; ANOVA). Net release of t-PA activity
nduced by bradykinin was less in smokers than nonsmokers
p 0.032, smokers versus nonsmokers; ANOVA) (Fig. 2).
radykinin caused no change in net PAI-1 antigen or
ctivity and did not affect vWF antigen in either group (p
.91, nonsmokers; p  0.98 nonsmokers; ANOVA). As
xpected (20). sodium nitroprusside caused no change in
bsolute or net release of t-PA, PAI-1 or vWf (data not
hown).
Plasma von Willebrand FactorConcentrations Du i g SFLLRN and Bradykinin I
Table 3 Plasma von Willebrand FactorConcentrations During SFLLRN and
Nonsmoker
Arm Infused
Baseline 0.72 0.05
Pre-SFLLRN 0.71 0.06
SFLLRN 5 nmol/min 0.70 0.03
SFLLRN 15 nmol/min 0.64 0.03
SFLLRN 50 nmol/min 0.70 0.04
Pre-BK 0.74 0.06
BK 100 pmol/min 0.76 0.07
BK 300 pmol/min 0.76 0.06
BK 1000 pmol/min 0.78 0.06
bsolute Plasma t-PA Antigen and Activity Concentrations
Table 2 Absolute Plasma t-PA Antigen and Activity Concentrat
t-PA Antigen (ng/ml)
Nonsmokers Smoke
Arm Infused Noninfused Infused
Baseline 8.15 2.18 8.33 2.24 10.83 1.94
Pre-SFLLRN 8.08 2.07 8.41 1.92 11.35 2.2
SFLLRN 5 nmol/min 7.84 2.23 7.68 1.76 9.91 2.08
SFLLRN 15 nmol/min 7.46 2.08 7.74 2.00 10.56 1.85
SFLLRN 50 nmol/min 11.54 2.82* 6.93 1.87 12.08 2.58
Pre-BK 7.14 1.68 8.17 2.43 10.66 1.99
BK 100 pmol/min 9.39 1.76 7.55 2.19 12.82 2.76
BK 300 pmol/min 9.32 1.55 8.23 2.42 13.66 2.66
BK 1000 pmol/min 11.55 1.77* 8.44 1.57 17.82 3.49†
ne-way analysis of variance for dose response: *p  0.005, †p  0.01; 2-way analysis: ‡p  0.
BK  bradykinin; t-PA  tissue-type plasminogen activator.One-way analysis of variance for dose response, p  NS for all; 2-way analys
BK  bradykinin.iscussion
o our knowledge, we have shown for the first time that
hrombin-mediated vascular responses are markedly im-
aired in cigarette smokers, with a substantial reduction
bserved in PAR-1–mediated endothelial t-PA release and
orearm arterial vasodilation. This impaired vasomotor and
brinolytic response may represent an important shift in the
ne balance between intravascular thrombosis and fibrino-
ysis that could account for the increased incidence of
therothrombosis in cigarette smokers.
moking and PAR-1–induced arterial vasomotion. As
eported by others (16), we observed no effect of smoking
tatus on endothelium-dependent vasodilation to bradyki-
in or endothelium-independent vasodilation to sodium
itroprusside. One of the important novel observations from
ur study is that vasodilation evoked via PAR-1 is impaired
n smokers, especially at the greater doses of SFLLRN.
ecause homeostatic mechanisms attempt to maintain ves-
el patency and minimize intravascular thrombus formation
n healthy arteries, we have previously hypothesized the
rterial vasodilation to PAR-1 activation represents a pro-
ns
ykinin Infusions
illebrand Factor Antigen (ng/ml)
Smokers
nfused Infused Noninfused
 0.19 0.77 0.09 0.78 0.13
 0.06 0.79 0.07 0.71 0.09
 0.05 0.72 0.10 0.73 0.06
 0.03 0.78 0.06 0.63 0.06
 0.04 0.78 0.06 0.63 0.06
 0.05 0.84 0.10 0.74 0.08
 0.05 0.78 0.08 0.71 0.05
 0.05 0.83 0.08 0.68 0.08
 0.05 0.83 0.08 0.76 0.07
t-PA Activity (IU/ml)
Nonsmokers Smokers
infused Infused Noninfused Infused Noninfused
 2.23 0.48 0.08 0.45 0.06 0.36 0.07 0.35 0.07
 2.29 0.54 0.08 0.44 0.05 0.41 0.07 0.40 0.07
 2.70 0.63 0.07 0.51 0.05 0.44 0.08 0.44 0.08
 2.52 0.84 0.11 0.59 0.06 0.56 0.11 0.50 0.08
 2.73 2.01 0.38* 0.65 0.09 0.78 0.18†‡ 0.49 0.10
 2.12 0.55 0.06 0.53 0.07 0.35 0.08 0.40 0.08
 2.11 1.55 0.21 0.54 0.07 0.84 0.15 0.45 0.07
 2.78 2.15 0.31 0.74 0.10 1.60 0.29 0.57 0.12
 2.70 3.51 0.40* 0.97 0.12 2.25 0.45*‡ 0.73 0.13§
 0.05 smokers versus nonsmokers.nfusio
Brad
von W
s
Noni
0.75
0.80
0.74
0.73
0.74
0.74
0.73
0.74
0.76ions
rs
Non
10.93
11.15
11.51
10.83
11.17
10.54
10.44
12.42
12.48is of variance, p  NS for all.
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July 1, 2008:33–9 PAI-1 Vasodilation and Fibrinolysis in Smokersective feedback mechanism. In the presence of a developing
hrombus, PAR-1–mediated vasodilation will increase
lood flow to limit arterial thrombosis by facilitating its
apid clearance and dissolution (14). Thus, this specific
bsolute Plasma PAI-1 Antigen and Activity Concentrations
Table 4 Absolute Plasma PAI-1 Antigen and Activity Concentra
PAI-1 Antigen (ng/ml)
Nonsmokers Smo
Arm Infused Noninfused Infused
Baseline 23.58 3.93 23.46 3.71 40.09 8.13
Pre-SFLLRN 21.25 3.35 21.68 3.12 33.9 7.19
SFLLRN 5 nmol/min 21.03 3.23 21.81 3.36 38.52 10.65
SFLLRN 15 nmol/min 22.28 3.55 21.13 3.18 37.63 9.06
SFLLRN 50 nmol/min 31.56 4.33* 20.52 3.20 53.64 10.20†
Pre-BK 24.16 3.86 21.58 3.27 38.44 9.67
BK 100 pmol/min 24.83 4.30 21.83 3.13 38.13 9.93
BK 300 pmol/min 22.13 3.24 23.68 4.17 39.42 0.39
BK 1,000 pmol/min 20.57 3.20 20.62 2.91 34.53 8.63
ne-way analysis of variance for dose response: *p  0.05, †p  0.0005; 2-way analysis of varia
BK  bradykinin; PAI-1  plasminogen activator inhibitor type 1.
Figure 2 Net Release of t-PA Activator
in Smokers and Nonsmokers
Net t-PA antigen (circles) and activity (squares) release induced by SFLLRN
(top panels) and bradykinin (bottom panels) in smokers (blue symbols) and
nonsmokers (red symbols). *p  0.05, †p  0.005. NS  nonsignificant
(analysis of variance, smokers vs. nonsmokers); t-PA  tissue-type plasmino-
gen activator.Pmpairment of PAR-1–induced vasodilation may have ma-
or pathophysiological consequences during acute throm-
otic events such as myocardial infarction.
moking and PAR-1–induced release of endothelium-
erived factors. Over and above diminished vasomotion,
he major finding of our study was the almost complete
bolition of PAR-1–mediated t-PA antigen release in
igarette smokers. Furthermore, PAR-1 activation caused
nly a very modest increase in t-PA activity despite causing
ubstantial t-PA antigen and activity release in nonsmokers.
The current findings confirm previous studies from our
wn and other groups reporting reduced t-PA release in
igarette smokers (15,16,18). Although not demonstrated
ith t-PA antigen, the present finding of reduced bradyki-
in induced active t-PA release is consistent with similar
bservations previously reported by Pretorius et al. (16)
owever, the magnitude of the reduction in t-PA release is
ubstantially greater for PAR-1–evoked responses than it is
or bradykinin or substance P (96% vs. 40% to 50%) (15,16).
e would therefore argue that SFLLRN-evoked t-PA
elease has the potential to be a more sensitive and patho-
hysiologically relevant assessment of endothelial vasomotor
nd fibrinolytic function.
Of note, PAR-1 activation also caused the release of
AI-1 antigen but did not cause an appreciable increase in
AI-1 activity, and neither indices were altered by smoking
tatus. This increase in PAI-1 antigen without a change in
ctivity suggests that SFLLRN is releasing PAI-1 from
latelets rather than the endothelium because platelet-
erived PAI-1 is relatively inactive as a result of the absence
f the stabilizing effects of vitronectin (16,21). Furthermore,
ur own recent work has demonstrated a concomitant
ncrease in beta-thromboglobulin, suggesting degranulation
f platelet alpha granules (22). Therefore, the contribution
f the endogenous fibrinolytic system to the prothrombotic
tate found in cigarette smokers is likely to be driven by
mpaired endothelial t-PA release and not by alterations in
PAI-1 Activity (AU/ml)
Nonsmokers Smokers
oninfused Infused NonInfused Infused Noninfused
.56 5.50 0.80 0.15 0.86 0.15 1.48 0.48 1.55 0.60
.08 5.06 0.63 0.12 0.73 0.13 1.52 0.56 1.57 0.63
.03 6.04 0.62 0.12 0.71 0.14 1.52 0.56 1.80 0.61
.92 6.07 0.58 0.12 0.72 0.13 1.65 0.53 1.63 0.63
.97 5.86 0.55 0.13 0.72 0.14 1.59 0.50 1.60 0.67
.41 8.37 0.79 0.17 0.81 0.16 1.74 0.57 1.70 0.69
.44 7.90 0.66 0.18 0.77 0.17 1.54 0.53 1.78 0.75
.10 8.23 0.56 0.16 0.76 0.19 1.58 0.56 1.35 0.47
.11 6.57 0.45 0.13 0.62 0.16 1.33 0.50 1.19 0.40
 NS for all, smokers versus nonsmokers.tions
kers
N
34
33
32
32
34
37
37
37
32AI-1 release or activity.
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PAI-1 Vasodilation and Fibrinolysis in Smokers July 1, 2008:33–9AR-1 activation as a pathophysiologically relevant
arker of endothelial function. The authors of previous
tudies to assess the endothelial release of endogenous
brinolytic factors have used diverse methods. Historical
eans of stimulating t-PA release have included the sys-
emic intravenous infusion of desmopressin and bradykinin,
ut this method causes significant confounding effects by
ltering systemic hemodynamics, activation of the sympa-
hetic nervous system, and concomitant release of other
ediators (6). By assessing the regional release of t-PA and
AI-1 in response to locally acting agonists, we can avoid
uch confounding effects.
We have previously demonstrated that substance
-induced t-PA release in the coronary (17) and peripheral
15) arterial circulations is impaired in cigarette smokers,
nd allows one to predict future adverse cardiovascular
vents in patients with coronary heart disease (11). How-
ver, although substance P has been a useful pharmacologic
ool, it is unclear whether substance P is likely to act as a
ajor pathophysiological mediator in atherothrombosis. In
ontrast, bradykinin may have a more direct role because it
s released during the contact phase of coagulation and there
s enhanced activation of the kallikrein system and brady-
inin release in patients with acute coronary syndromes
23). However, we would argue that, given its central role in
hrombosis and inflammation, thrombin is the most pow-
rful and pathophysiologically relevant mediator in this
etting. Our present findings not only reinforce previous
ndings but give the clearest indication yet that impaired
ndothelial function is of critical and dynamic importance in
he setting of coronary heart disease and acute coronary
yndromes.
moking and endothelium-dependent mechanisms. We
ave previously demonstrated that PAR-1 mediates ar-
erial vasodilation via 2 endothelium-dependent mecha-
isms, namely nitric oxide (NO) and endothelium-
erived hyperpolarizing factor (EDHF) (22). The
athways via which PAR-1 activation causes the endo-
helial release of t-PA are less clear and, in fact, inhibi-
ion of NO synthesis causes augmented SFLLRN-
nduced t-PA release (22). This discrepancy has raised
he question as to whether EDHF is responsible for t-PA
elease and, in the absence of NO, whether EDHF
esponses undergo a compensatory up-regulation. Al-
hough the bulk of evidence suggests that smoking
redominantly affects endothelial function by increasing
xidative stress with consequent disruption of NO pro-
uction (24,25), studies specifically examining the effect
f smoking upon EDHF-mediated responses are lacking.
tudy limitations. The forearm circulation has been an
xtremely reliable model for the assessment of vascular physi-
logy and pathophysiology. We do accept that our findings in
he forearm may not be accurately representative of the
oronary circulation. However, we and others have previously
emonstrated consistent findings of impaired endothelial t-PA
elease in both the forearm (15,16) and coronary (17,18)irculations of cigarette smokers. Although the forearm vascu-
ar bed is relatively protected from the development of ather-
ma, it therefore seems likely that changes in its fibrinolytic
apacity are indicative of the coronary circulation.
Establishing the receptor-mediated effects of thrombin in
he vasculature is of major physiological and therapeutic
elevance. It could be argued that, in our studies, the safety
equirement for the coadministration of tirofiban with
FLLRN detracts from these advantages. However, we
sed locally active doses of glycoprotein IIb/IIIa inhibitor
hat abolish SFLLRN-mediated platelet aggregation with-
ut affecting platelet-monocyte binding, a sensitive marker
f platelet activation. Furthermore, it has no effect upon
asal forearm blood flow or fibrinolytic responses to
FLLRN (14). We therefore believe that SFLLRN remains
n important and relevant tool to assess these fundamental
athophysiological aspects of endothelial function.
We have demonstrated an important impairment of
brinolytic capacity in smokers, but it remains unclear
hether this reflects an impairment of synthesis, storage,
nd release of t-PA, or indeed acceleration of its degrada-
ion. Addressing these questions will be challenging and is
ikely to require specifically designed in vitro studies.
onclusions
n healthy vessels, thrombin’s powerful procoagulant and
rothrombotic effects are offset by its ability to evoke the
elease of t-PA and induce arterial vasodilation. We have
hown here that cigarette smoking causes a marked impair-
ent in PAR-1–mediated endothelial vasomotor and fi-
rinolytic function. Relative arterial stasis and abolition of
-PA release will strongly enhance clot expansion and vessel
cclusion. Taken together, these findings suggest a major
ontribution of impaired endothelial PAR-1 action to the
ncreased atherothrombotic risk of smokers. These impor-
ant and novel findings are of direct relevance to our
nderstanding of the pathophysiology by which cigarette
moking causes an increased propensity to atherothrombotic
isorders including acute myocardial infarction and stroke.
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